This is an optional, add-on layer of testing — not part of our core seven-test mental health bundle. We order it case by case, when something in the clinical picture raises the question of a neuro-immune contributor, and we’re deliberate about suggesting it because it answers a specific question rather than a general one. It belongs in the workup when the presentation itself points toward immunity, not as a routine screen for everyone.
It pairs two panels from Vibrant Wellness, both run from a single blood draw with results returning in roughly two to three weeks. The first is the Neural Zoomer Plus, which screens for antibodies directed against neural and neurological tissues — the kind of self-directed immune activity that, in its most established form, underlies autoimmune encephalitis. The panel looks across multiple antigen targets to characterize whether, and where, the immune system may be reacting against the nervous system. The second panel, described next, widens the lens.
The Immune Zoomer widens the lens from the brain to the immune system as a whole. It characterizes autoimmune tendency and immune dysregulation more broadly, which provides context for any neural findings — an isolated neural antibody reads differently against a backdrop of quiet immunity than against clear systemic autoimmune activity. Together, the two panels ask not just "is there a neural antibody?" but "what is the immune system doing overall, and does the pattern hang together?"
Free 15-minute consultation to discuss your situation, answer your questions, and determine if we’re a good fit.
The clinical reality that makes this testing meaningful is well established at the severe end of the spectrum. Anti-NMDA receptor encephalitis — an autoimmune disease in which antibodies disrupt receptor signaling — frequently begins with rapidly progressive psychiatric symptoms, and at onset it can be genuinely difficult to distinguish from a primary psychiatric disorder [1]. That recognition has driven a broader question in psychiatry: whether some presentations of psychosis and treatment-resistant illness, without the full neurological syndrome, reflect an autoimmune process. An international consensus has proposed a careful, staged approach to identifying “autoimmune psychosis” precisely because neuronal autoantibodies have been found in people with otherwise isolated psychiatric presentations who then responded to immunotherapy [2].
It’s worth being precise about what that research does and doesn’t license. What it establishes is that neuro-immune mechanisms in psychiatric presentations are real — not that any one commercial panel confirms them. The consensus diagnostic pathway relies on specific, validated assays run in specialist settings; the Neural Zoomer Plus is a broader screen that raises questions worth pursuing, not a substitute for that pathway.
An immune lens also fits how we already think. Functional medicine treats the immune system as one of the connected systems driving mental health, alongside the gut, hormones, nutrients, and inflammation — so a neuro-immune finding rarely stands alone. It usually corroborates, or is corroborated by, what shows up on gut, inflammatory, and nutrient testing, and that convergence is part of what makes a result worth taking seriously.
This is the value of the testing, and also exactly where restraint is required. The data can surface a signal that reframes a stuck case. It cannot, by itself, hand you a diagnosis.
When a neural or immune finding turns up, it becomes a starting point for further investigation, not an endpoint. A meaningful result is something we bring into coordination with the appropriate medical specialists — neurology, immunology, or your psychiatric prescriber — because a suspected autoimmune contributor to mental health is a medical question that reaches beyond functional medicine alone. On the functional side, findings inform how we think about inflammation, immune regulation, and the gut-immune interface as part of your broader picture.
Because this is an add-on rather than part of the standard bundle, it sits alongside the core testing rather than replacing any of it. It also has a companion add-on: leaky brain and neurotransmitter testing, which examines blood-brain barrier integrity and neurotransmitter patterns and is often relevant in the same kinds of complex, treatment-resistant presentations.
If you've had related testing — prior autoimmune panels, or a neurological workup — bring the results. Existing data helps us decide whether this add-on will actually change the picture before ordering it.
We consider neural autoantibody and immune testing case by case, most often for:
A note on the limits — stated plainly, because this is the page most at risk of overpromising. Neural autoantibody testing is an active and evolving area of research, and the interpretation of these panels outside classic autoimmune encephalitis is not fully settled. A positive result is a signal to investigate further, not a diagnosis in itself — antibodies can appear without causing disease, and their clinical meaning depends heavily on the whole picture. We do not use these panels to declare an autoimmune cause of anyone’s mental health condition. We use them to decide whether a line of investigation is worth pursuing with the right specialists, and we say so directly. Two boundaries follow from that. If autoimmune encephalitis is genuinely suspected — the abrupt, severe, rapidly progressing picture — that is an urgent neurology workup, not an add-on panel, and we refer accordingly rather than testing around it. And a negative result on this panel does not rule out an autoimmune process: these screens don’t capture everything, so a normal result narrows the question without closing it. Full structure:
Free 15-minute consultation to discuss your situation, answer your questions, and determine if we’re a good fit.